28.2 C
Vientiane
Tuesday, July 8, 2025
spot_img
Home Blog Page 879

EcoFlow Launches DELTA 3 Plus and RIVER 3 Plus in Australia

SYDNEY, Feb. 17, 2025 /PRNewswire/ — EcoFlow is introducing two new portable power solutions, designed to give Australians flexible, innovative and reliable energy for every situation. The EcoFlow DELTA 3 Plus is a dependable home power backup solution that you can also take anywhere, from RVs and caravans to tents and outdoor adventures. The EcoFlow RIVER 3 Plus is a lightweight, easy-to-carry power station built for entry-level users who need a steady source of power while camping, on road trips, or driving across the country. With a simple design and consistent powerful performance, these new solutions ensure Australians stay powered.

As Australians embrace the outdoors more than ever – taking over 15 million caravan and camping trips in 2023 – and with extreme weather events causing more frequent power outages, the need for available, portable power has never been greater. Whether preparing for blackouts due to the forces of mother nature, or staying powered off-grid, EcoFlow’s new products offer flexible energy solutions to meet the needs of Australians today.

Key product features:

EcoFlow DELTA 3 Plus:

Fast charging, powerful output and worry-free endurance. EcoFlow DELTA 3 is a reliable home power backup solution.
Fast charging, powerful output and worry-free endurance. EcoFlow DELTA 3 is a reliable home power backup solution.

  • Fast charging with a capacity of 1024kWH and 1800W output. For example, a 30-minute charge from an AC wall socket can provide enough backup power for a typical refrigerator for at least five hours.
  • Powerful output and ultra-quiet operation. With 11 outport ports, it can continuously power appliances up to 2400W, such as ovens, hair dryers and kettles – perfect for RVs, 4WD trips and home backup power. It runs quietly at just 30db; when using less than 600W, it blends into the background, making it virtually unnoticeable – ideal for use in a tent without disturbing sleep.
  • Compact design and portable. It is more portable compared to its predecessor, weighing 12.5kg. The weight is approximately equal to that of a family tent for two to three people.

EcoFlow RIVER 3 Plus:

Compact, 10ms professional uninterrupted power supply and fast charging. The EcoFlow RIVER 3 Plus is built for entry-level users.
Compact, 10ms professional uninterrupted power supply and fast charging. The EcoFlow RIVER 3 Plus is built for entry-level users.

  • Compact and long-lasting runtime. Weighing only 4.7kg, it is designed to be taken anywhere that needs quick and reliable power. It also offers a 286Wh capacity, which can power your Wi-Fi router up to 35 hours.
  • Fast-charging with multiple charging methods. Traditional home UPS batteries often take eight hours or more to recharge and usually only support AC charging. With its fast charge technology, it significantly reduces AC charging time to just one hour, without damaging the battery. It also supports many charging options, including solar, car and generator.
  • 10ms UPS capability. In an event of a power outage, it can prevent issues like food spoilage from fridge shutdowns, or data loss from sudden computer failures, ensuring essential devices stay powered without interruption.

Both the EcoFlow DELTA 3 Plus and EcoFlow RIVER 3 Plus are available from today via the EcoFlow Australia website, eBay Australia and Amazon Australia.  

The EcoFlow DELTA 3 Plus is $1,599 and the EcoFlow RIVER 3 Plus is $499.

Earlier this month, EcoFlow also launched EcoFlow RIVER 3 (UPS). Its ultra-fast UPS makes it the perfect companion for outdoor adventures.

Images and more information can be found in the below respective media kits.  

About EcoFlow 

EcoFlow is a leading provider of eco-friendly energy solutions, committed to powering a new world. Since its founding in 2017, EcoFlow has aimed to be the FIRST in power solutions — Flexible, Innovative, Reliable, Simple, and Thorough — for individuals and families, whether at home, outdoors or on the go. With a smart manufacturing center in China, and headquarters in the USA, Germany and Japan, EcoFlow has empowered over 4.5 million users in 140 markets worldwide. For more information, visit https://www.ecoflow.com/au

Media Contact
Allison Worldwide for EcoFlow Australia 
ecoflowanz@allisonworldwide.com  

Navi Medical Technologies’ Neonav® ECG Tip Location System Receives FDA 510(k) Clearance

Revolutionising Vascular Access Care for Critically Ill Newborns and Children

Key Points:

  • FDA 510(k) Clearance Neonav® ECG Tip Location System is now FDA-cleared, enabling its use in U.S. hospitals to enhance pediatric vascular access care.
  • First-of-its-kind Innovation: Neonav® is the only system designed specifically for neonatal and pediatric patients, using real-time ECG signal analysis to ensure accurate placement of Central Venous Access Devices (CVADs), significantly reducing risks like misplacement and migration.
  • U.S. Market Expansion: With clearance secured, and offices in Australia and the United States, Navi Medical Technologies plans to raise capital and engage hospital networks to bring Neonav® to U.S. healthcare providers.
  • Australian Innovation on the Global Stage: Based in Melbourne, Navi is demonstrating how Australian medtech can revolutionize global pediatric care.

MELBOURNE, Australia, Feb. 17, 2025 /PRNewswire/ — Navi Medical Technologies, a medical device company focused on pediatric healthcare innovation, proudly announces that its Neonav® ECG Tip Location System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

This milestone represents a significant step forward in vascular access care for critically ill newborns and children worldwide. The Neonav® is the first medical device of its kind specifically designed for neonatal and pediatric care. By using real-time ECG signal analysis, it aids accurate placement of Central Venous Access Devices (CVADs), significantly reducing the risks associated with misplacement and migration which can cost US hospitals up to USD$1 Billion per year. This breakthrough innovation minimises reliance on confirmatory chest X-rays, will help in reducing delays in care, as well as lowering unintended complications for vulnerable patients.

World-First Technology Tailored for Pediatric Patients

The Neonav® system has the broadest ‘Indication For Use’ of any tip location system on the market, covering preterm newborns through to adults. Importantly, the system can be used to place tiny 1Fr catheters used in very small newborns, and is cleared for placement of catheters both above and below the heart. The system has also been developed to enable ongoing surveillance of catheters after the initial placement, an important first which can help to prevent potentially serious healthcare complications resulting from undiagnosed movement of the tip of the catheter. These novel features address critical challenges faced by healthcare professionals in neonatal and pediatric care.

Dr Janene Fuerch is a Neonatologist at Stanford Children’s Health, and is excited about the prospect of the Neonav being available to assist with the treatment of  children in the United States, “Central lines are lifesaving but can be challenging to position. We need a guidance system to tell us when we are in the correct location. The Neonav system fulfills that need and gives a characteristically blind procedure a way to move forward, telling you exactly where you are and how to move into the correct position”

Strategic Growth & U.S. Expansion

With FDA clearance secured, and offices in Australian and the United States, Navi Medical Technologies will seek to raise capital later this year to support its entry into the U.S. market, “We recognize the tremendous opportunity to bring our ground-breaking technology to the U.S., and we will continue to engage hospital networks and potential partners that can help ensure that our innovations reach the patients who need them most” said Alex Newton, CEO of Navi.

“With FDA clearance in hand, we’re uniquely positioned to drive significant impact in the largest healthcare market in the world. Our investors have the chance to be part of a mission that’s not only financially rewarding but also deeply meaningful. By working together, we can ensure that every critically ill child has access to safer, faster, and more effective care.”

Backed by Leading Healthcare Innovators & Partners

Navi Medical Technologies acknowledges the invaluable support of its investors and partners, including Breakthrough Victoria, The Royal Women’s Hospital, the Australian Federal and Victorian Governments, MTPConnect, and the US FDA Pediatric Device Consortia program. Their backing has been instrumental in achieving this milestone and advancing Navi’s mission to improve pediatric healthcare worldwide.

“We wouldn’t be here without the backing of our investors and partners,” said Alex. “Their support and belief in our vision has enabled us to reach this point and set the stage for global expansion. We’re deeply grateful for their ongoing commitment to innovation and healthcare improvement.”

An Australian Success Story

The FDA clearance highlights Australia’s thriving medtech sector. Minister for Economic Growth and Jobs Danny Pearson celebrated the achievement:

“This local Victorian company will be taking its home-grown technology to the United States – helping make hospital care safer for critically ill newborn babies on the other side of the world.”

Victoria is the medical research capital of Australia – this is a booming industry that is backing economic growth and quality advanced manufacturing jobs across our state.”

Breakthrough Victoria, an investor in Navi, also praised the company’s progress. CEO Rod Bristow commented: “As an investor, we are excited about Navi’s trajectory and its potential to become a leader in the paediatric medical device market. With strong fundamentals, regulatory validation, and a clear pathway to commercialisation, Navi represents a compelling investment opportunity with both financial and wider societal impact.”

About Navi Medical Technologies

Navi Medical Technologies is a Melbourne-based medtech company dedicated to advancing pediatric healthcare. By collaborating with leading clinicians, Navi develops breakthrough technologies that improve outcomes for the most vulnerable patients.

Email: info@navitechnologies.com 
Website: www.navitechnologies.com

Documentary A Bite of China (Season 4) Sparks Discussion: Cultural Ripples from Culinary Encounters

BEIJING, CHINA – Media OutReach Newswire – 15 February 2025 – Cultural exchange has become an essential bridge for communication between nations. Recently, products associated with China, such as the AI technology DeepSeek, the animated film Ne Zha 2, and the food documentary A Bite of China (Season 4), have converged to create a powerful wave of “Chinese style” that is making waves across the globe. Among these, A Bite of China (Season 4) has opened the taste buds of global audiences, allowing them to explore Chinese culture through the universal topic of food. As the documentary gains popularity, a series of visually stunning short videos have gone viral on major social media platforms, attracting media attention and coverage from countries and regions including Portugal, Canada, Japan, South Korea, South Africa, Italy, Dubai, Greece, and Peru.

For a long time, Chinese cuisine abroad has been stereotyped as “convenient,” “takeout,” and “sweet and sour.” However, A Bite of China (Season 4) uses exquisite cinematography to reveal the rich stories and Eastern philosophy behind Chinese food. From its journey across the seas to local adaptations and deep integration with foreign cuisines, Chinese food has sparked cultural ripples, blending and merging with other culinary traditions worldwide.

One particularly striking scene in the documentary shows a street in Paris, where blonde-haired, blue-eyed diners shout “Dao Xiao Mian” (knife-cut noodles) in Chinese. Meanwhile, a Chinese woman in a food truck skillfully slices dough into leaf-like noodles with a curved knife, dropping them into a bubbling pot. This traditional Chinese noodle dish, with its “Chinese kung fu” of kneading and resting, allows French diners to experience authentic Eastern craftsmanship passed down through millennia. One viewer commented on social media, “Watching Chinese chefs cook is like watching a spectacular performance; their hands seem magical, transforming ordinary ingredients into delicious dishes in no time.”

In addition to the authentic journey of Chinese cuisine, Chinese food culture is taking root in various corners of the world, blending and coexisting with local culinary traditions. Southeast Asia’s Nyonya cuisine reflects the wisdom and aesthetic of Chinese dining, with each flavor echoing the Chinese community’s longing for the tastes of their homeland. Michelin-starred chef Adeline in France showcases her “Sino-French fusion” philosophy by using a Chinese wok to prepare the famous French dish bouillabaisse, replacing frying pans with steamers for foie gras, and incorporating Shaoxing wine, a Chinese flower wine, into a white sauce. She also uses Zhenjiang vinegar paired with cinnamon to create a black vinegar sauce. Familiar ingredients, yet unfamiliar flavors, allow French diners to enjoy a delightful culinary experience.

As the world collectively celebrates the first Spring Festival following its successful application for UNESCO recognition, the popularity of A Bite of China (Season 4) is ushering in a new wave of global interest in Chinese cuisine. Foreign viewers are experiencing the vibrant atmosphere of the Spring Festival and the diversity of Chinese food culture, with comments such as, “I used to only know General Tso’s chicken and Mapo tofu, but after watching the documentary, I realized how vast the world of Chinese cuisine is. I want to visit a Chinese restaurant during the Spring Festival to try more delicious dishes.”

The fusion of Chinese and foreign cuisines is not limited to restaurants; it has also permeated the daily lives of ordinary people. In traditional markets in France, Chinese vinegar is displayed alongside Italian balsamic vinegar; in various Southeast Asian countries, Chinese restaurants are transforming from “exclusive to Chinese” to “national cuisine”; in American classrooms, Chinese cuisine has become a subject for global students to understand and learn.

At the same time, China is welcoming the world with a more open attitude. Recent visa facilitation policies for foreigners have made it fashionable to “check in” on Chinese customs and traditions. The airing of A Bite of China (Season 4) will undoubtedly spark more interest among foreigners in Chinese cuisine, encouraging them to experience this land firsthand—tasting freshly made jianbing (Chinese crepes) in the alleys, savoring West Lake vinegar fish in the waters of Jiangnan, and feeling the heat of spicy hotpot in the streets of Sichuan and Chongqing.

As the documentary states, “If there truly exists a clear culinary map of the world, it certainly would not have clear national borders.” When French diners pick up knife-cut noodles with chopsticks, when Silicon Valley elites have Shanghai wontons on their plates, and when the British public falls in love with “spicy” and “fish fragrant” flavors, they are not just tasting a symphony created by Chinese cooking techniques; they are experiencing the passion of an ancient civilization for life.

Hashtag: #ABiteofChina

The issuer is solely responsible for the content of this announcement.

Vantage Honored with Three Prestigious Awards at the 5th Annual Business Tabloid Awards

PORT VILA, Vanuatu, Feb. 15, 2025 /PRNewswire/ — Vantage Markets is proud to announce its success at the 5th Annual Business Tabloid Awards, held on 23rd January 2025 in Dubai. The Annual Business Tabloid Awards celebrate outstanding achievements across industries, including banking, finance, technology, and leadership. Winners are selected by a panel of industry experts, who evaluate nominees based on innovation, performance, and impact. Receiving three awards at this distinguished event reflects Vantage’s global commitment to excellence in the financial services industry.

Vantage Wins Big at the 5th Annual Business Tabloid Awards
Vantage Wins Big at the 5th Annual Business Tabloid Awards

  • Best CFD Broker – APAC: This award reflects Vantage’s leadership in providing advanced tools, competitive pricing, and tailored solutions for traders.
  • Best Value Broker – LATAM: Vantage’s dedication to delivering cost-effective trading solutions while maintaining exceptional quality earned it this distinction.
  • Best Trading Platform – MENA: This recognition underscores Vantage’s investment in cutting-edge technology and its commitment to meeting the unique needs of traders.

Vantage Wins Big at the 5th Annual Business Tabloid Awards
Vantage Wins Big at the 5th Annual Business Tabloid Awards

The event brought together industry leaders and influencers to celebrate excellence across various sectors, including banking, finance, technology, and trading. The evening commenced with a networking session, providing an invaluable opportunity for professionals to connect and exchange insights. Followed by the award presentation ceremony, where Vantage was honored for its excellence, reflecting its commitment to providing quality trading solutions.

Marc Despallieres, CEO of Vantage Markets, shared his thoughts on the achievement: “Winning these three awards at the Business Tabloid Awards is a testament to our commitment to excellence, innovation, and client-centricity. These accolades reflect the hard work of our team and the trust our clients place in us. We are proud to have been recognized for our excellence in APAC, LATAM, and MENA, reflecting our commitment to empowering our traders.”

As Vantage continues to expand its presence and deliver value to its clients, the company is committed to maintaining its reputation for excellence and innovation.

For more information on Vantage’s award-winning services, visit Vantage Markets.

About Vantage

Vantage Markets (or Vantage) is a multi-asset CFD broker offering clients access to a nimble and powerful service for trading Contracts for Difference (CFDs) products, including Forex, Commodities, Indices, Shares, ETFs, and Bonds.

With over 15 years of market experience, Vantage transcends the role of broker, providing a trusted trading ecosystem, an award-winning mobile trading app, and a user-friendly trading platform that empowers clients to seize trading opportunities. Download the Vantage App on App Store or Google Play.

trade smarter @vantage

Important Notice: This article is for informational purposes only and does not constitute an offer or solicitation of Vantage’s services in any jurisdiction. Vantage’s services may not be available in all regions mentioned and are subject to strict regulatory requirements. Before engaging with our services, please check your local regulations to ensure you are eligible to access our products and services in your region.

RISK WARNING: CFD trading carries significant risks. You could lose more than your initial investment.

SCIA boosts global ventures of Chinese enterprises

BEIJING, Feb. 15, 2025 /PRNewswire/ — A news report from chinadaily.com.cn:

View of 2025 SCIA Spring Reception.
View of 2025 SCIA Spring Reception.

As the global influence of the Guangdong-Hong Kong-Macao Greater Bay Area in arbitration continues to grow, the Shenzhen Court of International Arbitration, or SCIA, is supporting Chinese business enterprises in their global ventures.

It’s also contributing to international trade and economic exchanges, according to industry experts and corporate representatives at a dialogue held on Feb 12 in Shenzhen, South China’s Guangdong province.

SCIA council members from Hong Kong, Macao and overseas, along with over 50 representatives from major Chinese companies, discussed global economic trends, challenges and opportunities for Chinese enterprises.

They highlighted the crucial role of international arbitration in resolving disputes in trade, investment, finance and maritime commerce. 

Liu Xiaochun, SCIA president and executive chairman of the South China International Arbitration Center (HK), stressed the importance of leveraging international rules and Hong Kong and Macao’s strengths to protect the rights of Chinese enterprises overseas.

“We need to build a stable, transparent, fair and predictable market-oriented, rule-of-law and international business environment,” he said. 

Under the framework of “one country, two systems and three legal jurisdictions”, the SCIA aligns rules with Hong Kong and Macao to facilitate business in common law and Portuguese-speaking countries.

Liu noted that Hong Kong’s resources connected SCIA to common law countries, while Macao’s unique legal system strengthened links to Portuguese and Spanish-speaking nations – providing professional and transparent dispute resolution services for Chinese enterprises. 

Roberto Azevêdo, SCIA council member and former director-general of the World Trade Organization, underscored that international dispute resolutions provided stability to global trade relations. He said that the SCIA played a vital role in ensuring robust mechanisms for resolving international commercial disputes.

Anthony Neoh, SCIA vice-chairman, highlighted the council’s international composition – including experts in China, from Hong Kong and Macao – which enhanced confidence in its legal and arbitration systems. 

“We are connected with judicial institutions in Shenzhen, Hong Kong and Macao. The courts and arbitration institutions across these three regions are organically integrated, enhancing confidence in our legal and arbitration systems,” Neoh added.

To better serve Chinese and foreign clients and meet the demand for risk prevention and dispute resolution in the international operations of enterprises, the SCIA continues to promote its international development.

In 2024, it accepted a record 14,518 commercial arbitration cases, with the total disputed amount reaching 142.27 billion yuan ($19.67 billion) – maintaining its position among the top three arbitration institutions globally.

The number of newly accepted international commercial arbitration cases rose to 520, a whopping year-on-year increase of 25.6 percent. Meanwhile, the geographic coverage of global clients expanded further, with parties from 64 countries and regions involved, representing a 45 percent year-on-year increase.

To date, the SCIA has served parties from a cumulative 142 countries and regions. Of its 2,087 arbitrators, currently, 733 are from overseas, accounting for 35.12 percent of the total.

HYPTEC HT Tops the Best-selling List of High-end Pure Electric SUV in Thailand for Two Consecutive Months

BEIJING, Feb. 15, 2025 /PRNewswire/ — The latest monthly sales data from Thailand show that HYPTEC HT, a premium model from the Chinese EV brand GAC HYPTEC, has become the best-selling high-end pure electric SUV in the Thai market for two months in a row.


As one of the most proactive countries in Southeast Asia when it comes to promoting electric vehicles, Thailand has seen a surge of Chinese EV brands entering the market in recent years, with GAC HYPTEC as a strong contender. The HYPTEC HT, with its all-encompassing premium features, has quickly become a sought-after “new luxury” vehicle among Thailand’s elites. The vehicle received widespread attention when it was officially delivered to Thai celebrity Thassapak Hsu (Bie) in October 2024, further solidifying its popularity.

Boasting a 2,935 mm wheelbase, striking gullwing doors, and a range of luxury features, including NAPPA leather upholstery across all variants, the HYPTEC HT offers a new level of intelligent luxury for families worldwide.


As global demand for electric vehicles continues to rise, Chinese NEV brands are among the first to make significant breakthroughs in the Thai market, with steady growth in sales figures. This success can be attributed to a keen understanding of the local market and in-depth insights into overseas consumers. GAC HYPTEC remains committed to its core values of “Technology, Luxury, and Classy” while prioritizing a user-centric approach. By staying focused on these guiding principles, GAC HYPTEC aims to drive its global expansion, turning the technological edge of Chinese EV brands into a distinct market advantage, helping them shine on the global automotive stage.

 

Shawn “JAY-Z” Carter Issues Statement After Jane Doe Lawsuit Regarding False Rape Allegations Gets Dismissed With Prejudice

NEW YORK, Feb. 15, 2025 /PRNewswire/ — Today, Shawn “JAY-Z” Carter issued the below statement in response to the dismissal of Tony Buzbee’s Jane Doe lawsuit with prejudice:

“Today is a victory. The frivolous, fictitious and appalling allegations have been dismissed. This civil suit was without merit and never going anywhere. The fictional tale they created was laughable, if not for the seriousness of the claims. I would not wish this experience on anyone. The trauma that my wife, my children, my loved ones and I have endured can never be dismissed.

This 1-800 lawyer gets to file a suit hiding behind Jane Doe, and when they quickly realize that the money grab is going to fail, they get to walk away with no repercussions. The system has failed.

The court must protect victims, OF COURSE, while with the same ethical responsibility, the courts must protect the innocent from being accused without a shred of evidence. May the truth prevail for all victims and those falsely accused equally.”

Carter’s attorney, Alex Spiro, also shared a statement in the wake of the dismissal of the lawsuit that Buzbee filed in December 2024, saying:

“The false case against JAY-Z, that never should have been brought, has been dismissed with prejudice. By standing up in the face of heinous and false allegations, Jay has done what few can – he pushed back, he never settled, he never paid 1 red penny, he triumphed and cleared his name.”

NBC News exposed the plaintiff’s false claims in a story published in December. The plaintiff originally told NBC News that she spoke with musician Benji Madden at the after party where the alleged assault took place, but a representative for Benji and his brother Joel confirmed to the publication that neither of the brothers attended the 2000 VMAs because they were on tour in the Midwest. Furthermore, the plaintiff said her father picked her up after the alleged assault, but he denied her account, telling NBC News that he “cannot verify the claims.”

The plaintiff’s fabricated lies further unraveled after she indicated that she watched the 2000 Video Music Awards show on a jumbotron outside of Radio City Music Hall. However, according to the New York Police Department, there was no permit issued for a jumbotron that year. She also said she “stumbled” upon a limousine despite the fact that the limousine area was blocks away from the venue.

The false claim that the assault took place at “a large white residence with a gated U-shaped driveway” in New York roughly a 20-minute drive from Radio City Music Hall on Sept. 7, 2000 was also debunked. It ultimately came to light that there were no houses in New York that matched the plaintiff’s descriptions within a 20-minute radius.

ASCO GU|RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer

YANTAI, China, Feb. 15, 2025 /PRNewswire/ — On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, USA, Professor Xinan Sheng from Peking University Cancer Hospital delivered the latest efficacy and safety data from the phase II clinical trial (NCT05297552, Study ID: RC48-C017) of Disitamab Vedotin (DV) in combination Toripalimab as the neoadjuvant therapy for HER2-expressing muscle-invasive bladder cancer (MIBC) in an oral presentation. This marks the first public disclosure of results from a prospective clinical study investigating an ADC drug in combination with an immunotherapy as a perioperative therapy for MIBC. The pathological complete response (pCR) rate reached an impressive 63.6%, which is a breakthrough improvement compared with traditional neoadjuvant chemotherapies (36%-42%). ASCO GU is one of the top urologic oncology conferences that leading experts worldwide in this field attend.

The NCT05297552 study explored the synergy between the targeted therapy and immunotherapy in the perioperative setting for MIBC. Specifically, it assessed the safety and efficacy of the novel combination therapy featuring DV, a HER2-targeting ADC drug initially developed by RemeGen Co., Ltd. (RemeGen), and Toripalimab, a PD-1 inhibitor. In May 2024, based on the NCT05297552 study, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) granted breakthrough therapy designation to DV. The preliminary results of this study were presented at the 2024 ASCO Annual Meeting and led to widespread attention and discussion among experts worldwide. The updated data at ASCO GU further validated the clinical benefits of this therapeutic approach.

In the NCT05297552 study, 47 eligible patients (10.6% with HER2 IHC 1+, 57.4% with IHC 2+, and 31.9% with IHC 3+) received the investigational neoadjuvant therapy, among whom 33 patients underwent radical cystectomy and pelvic lymph node dissection (RC + PLND). As of the data cut-off date on December 3, 2024, the study demonstrated promising efficacy and manageable safety profiles:

  • The pathological complete response (pCR) rate reached an impressive 63.6% (95% CI: 45.1% – 79.6%), nearly doubling that observed with traditional neoadjuvant chemotherapies (36%-42%). The pathological response rate was 75.8% (95% CI: 57.7% – 88.9%). The study showed that for patients with baseline clinical stage of T2N0, the postoperative pCR rate reached 85.7%. A pCR rate of 55.6% was also achieved in patients with other pathological subtypes of urothelial carcinoma at baseline. Patients benefited significantly regardless of PD-L1 positive/negative and regardless of HER2 expression status (IHC 1+/2+/3+), among whom the pCR rate stood at 84.6% for HER2 IHC 3+ patients.
  • The 12-month event-free survival (EFS) rate of all patients who underwent radical cystectomy was 92.5%, and the 18-month EFS rate was 85.9%.
  • The therapy exhibited a manageable safety profile. The incidence of grade 3 or higher treatment-emergent adverse events (TEAEs) was only 27.7%, notably lower than the traditional chemotherapy regimen (40%-50%), suggesting a favorable tolerability.

RemeGen is advancing research on targeted and personalized therapies for bladder cancer through indication expansion and therapy innovation of DV, aiming to provide more potent treatment options for patients worldwide. Currently, studies are in-progress to explore the feasibility of expanding DV-based regimens from later-line to front-line treatment for locally advanced or metastatic urothelial cancer. There are also plans to broaden the research of DV as a neoadjuvant therapy for MIBC to the entire perioperative period and investigate the synergy between DV and chemotherapy or other immunotherapies in treating urothelial cancer.